Equities

Chongqing Genrix Biopharmaceutical Co Ltd

688443:SHH

Chongqing Genrix Biopharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)22.48
  • Today's Change-0.47 / -2.05%
  • Shares traded1.61m
  • 1 Year change-29.60%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,920287441
Total Receivables, Net382532
Total Inventory555634
Prepaid expenses192922
Other current assets, total--1.45--
Total current assets3,032399529
Property, plant & equipment, net490491385
Goodwill, net------
Intangibles, net444546
Long term investments0.380.380.39
Note receivable - long term----18
Other long term assets1.261.200.95
Total assets3,5959621,003
LIABILITIES
Accounts payable836847
Accrued expenses373024
Notes payable/short-term debt0.6300
Current portion long-term debt/capital leases10137.41
Other current liabilities, total5.81167.70
Total current liabilities13712686
Total long term debt630769564
Total debt641782572
Deferred income tax------
Minority interest------
Other liabilities, total433841
Total liabilities810933691
SHAREHOLDERS EQUITY
Common stock367275275
Additional paid-in capital4,038573280
Retained earnings (accumulated deficit)(1621)(819)(243)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity2,78429312
Total liabilities & shareholders' equity3,5959621,003
Total common shares outstanding367367367
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.